Braidwell LP Decreases Stock Position in argenx SE (NASDAQ:ARGX)

Braidwell LP trimmed its position in argenx SE (NASDAQ:ARGX) by 42.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,724 shares of the company’s stock after selling 70,200 shares during the period. argenx comprises about 1.5% of Braidwell LP’s investment portfolio, making the stock its 26th largest position. Braidwell LP owned about 0.16% of argenx worth $52,432,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares during the period. Clearbridge Investments LLC grew its position in argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock valued at $265,535,000 after acquiring an additional 21,189 shares in the last quarter. Sei Investments Co. boosted its stake in shares of argenx by 15.2% during the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after buying an additional 50,477 shares during the last quarter. Alkeon Capital Management LLC boosted its stake in shares of argenx by 15.0% during the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock valued at $187,018,000 after buying an additional 45,000 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of argenx by 0.6% during the 3rd quarter. Jennison Associates LLC now owns 237,966 shares of the company’s stock valued at $128,997,000 after buying an additional 1,528 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Truist Financial raised their price objective on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and raised their price target for the company from $515.00 to $650.00 in a report on Friday, November 1st. JMP Securities lifted their target price on argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft lowered argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, argenx currently has an average rating of “Moderate Buy” and an average target price of $630.42.

argenx Trading Up 1.2 %

Shares of NASDAQ ARGX opened at $614.59 on Friday. The company has a market capitalization of $37.10 billion, a P/E ratio of -698.40 and a beta of 0.61. The stock has a 50 day moving average of $564.06 and a 200-day moving average of $494.46. argenx SE has a 12 month low of $327.73 and a 12 month high of $620.28.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period last year, the firm posted ($1.25) EPS. Analysts predict that argenx SE will post 2.2 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.